Literature DB >> 12545158

Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.

Alan E Bilsland1, Claire J Anderson, Aileen J Fletcher-Monaghan, Fiona McGregor, T R Jeffry Evans, Ian Ganly, Richard J Knox, Jane A Plumb, W Nicol Keith.   

Abstract

Reactivation of telomerase maintains telomere function and is considered critical to immortalization in most human cancer cells. Elevation of telomerase expression in cancer cells is highly specific: transcription of both RNA (hTR) and protein (hTERT) components is strongly upregulated in cancer cells relative to normal cells. Therefore, telomerase promoters may be useful in cancer gene therapy by selectively expressing suicide genes in cancer cells and not normal cells. One example of suicide gene therapy is the bacterial nitroreductase (NTR) gene, which bioactivates the prodrug CB1954 into an active cytotoxic alkylating agent. We describe construction of adenovirus vectors harbouring the bacterial NTR gene under control of the hTR or hTERT promoters. Western blot analysis of NTR expression in normal and cancer cells infected with adenoviral vectors showed cancer cell-specific nitroreductase expression. Infection with adenoviral telomerase-NTR constructs in a panel of seven cancer cell lines resulted in up to 18-fold sensitization to the prodrug CB1954, an effect that was retained in two drug-resistant ovarian lines. Importantly, no sensitization was observed with either promoter in any of the four normal cell strains. Finally, an efficacious effect was observed in cervical and ovarian xenograft models following single intratumoural injection with low doses of vector, followed by injection with CB1954.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12545158     DOI: 10.1038/sj.onc.1206168

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes.

Authors:  Rosalind M Glasspool; Sharon Burns; Stacey F Hoare; Catharina Svensson; W Nicol Keith
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

2.  Identification of an RNA aptamer binding hTERT-derived peptide and inhibiting telomerase activity in MCF7 cells.

Authors:  Akhil Varshney; Jyoti Bala; Baby Santosh; Ashima Bhaskar; Suresh Kumar; Pramod K Yadava
Journal:  Mol Cell Biochem       Date:  2016-12-21       Impact factor: 3.396

3.  Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Authors:  Alan E Bilsland; Aileen Fletcher-Monaghan; W Nicol Keith
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

4.  Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector.

Authors:  B-C Ahn; J A Ronald; Y I Kim; R Katzenberg; A Singh; R Paulmurugan; S Ray; L V Hofmann; S S Gambhir
Journal:  Gene Ther       Date:  2011-02-10       Impact factor: 5.250

5.  The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480.

Authors:  Yan Ding; Xiaobing Huang; Taiping Liu; Yong Fu; Zhangping Tan; Hong Zheng; Taoli Zhou; Jigang Dai; Wenyue Xu
Journal:  Pathol Oncol Res       Date:  2012-06-08       Impact factor: 3.201

Review 6.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

7.  Suppression of colorectal tumor growth by regulated survivin targeting.

Authors:  Binghua Li; Junkai Fan; Xinran Liu; Rong Qi; Linan Bo; Jinfa Gu; Cheng Qian; Xinyuan Liu
Journal:  J Mol Med (Berl)       Date:  2006-11-01       Impact factor: 4.599

8.  Plasmodium circumsporozoite protein suppresses the growth of A549 cells via inhibiting nuclear transcription factor κB.

Authors:  Xu-Feng Deng; Dong Zhou; Quan-Xing Liu; Hong Zheng; Yan Ding; Wen-Yue Xu; Jia-Xin Min; Ji-Gang Dai
Journal:  Oncol Lett       Date:  2018-02-26       Impact factor: 2.967

9.  Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma.

Authors:  Yue-Min Li; San-Tai Song; Ze-Fei Jiang; Qi Zhang; Chang-Qing Su; Guo-Qing Liao; Yi-Mei Qu; Guo-Qing Xie; Ming-Ying Li; Fei-Jiao Ge; Qi-Jun Qian
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

10.  Thymosin β10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production.

Authors:  Young-Chae Kim; Byoung-Gie Kim; Je-Ho Lee
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.